Identification of biomarkers of hypertrophic cardiomyopathy development and progression in Dutch MYBPC3 founder mutation carriers

Identification of biomarkers of hypertrophic cardiomyopathy development and progression in Dutch MYBPC3 founder mutation carriers - BIO FOr CARe

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47925

Enrollment

1000

Registered

2016-03-24

Start date

2017-01-12

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertrophic cardiomyopathy / thick heart muscle

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: MYBPC3 founder mutation carrier and 18 years or older

Exclusion criteria

Exclusion criteria: Cardiac transplant

Design outcomes

Primary

Measure	Time frame
Main study determinants/potential predictors - Age (at carrier diagnosis) - Gender - cMyBP-C protein content in exosomes isolated from plasma - creatine/guanidine acetic acid ratio in plasma - delta creatine/guanidine acetic acid ratio in plasma prior/after exercise test - acylcarnitine profile in plasma - delta acylcarnitine profile in plasma prior/after exercise test Dependent of the study question of the prospective cohort the endpoints are: 1) development of severe HCM 2) progression of HCM to severe HCM For the case-control study at baseline: a severe HCM phenotype. A severe cardiac phenotype will be defined as one or more of the following: septal thickness of >= 20 mm, cardiac arrest due to ventricular arrhythmia, LVEF	—

Measure

Time frame

Main study determinants/potential predictors - Age (at carrier diagnosis) - Gender - cMyBP-C protein content in exosomes isolated from plasma - creatine/guanidine acetic acid ratio in plasma - delta creatine/guanidine acetic acid ratio in plasma prior/after exercise test - acylcarnitine profile in plasma - delta acylcarnitine profile in plasma prior/after exercise test Dependent of the study question of the prospective cohort the endpoints are: 1) development of severe HCM 2) progression of HCM to severe HCM For the case-control study at baseline: a severe HCM phenotype. A severe cardiac phenotype will be defined as one or more of the following: septal thickness of >= 20 mm, cardiac arrest due to ventricular arrhythmia, LVEF

—

Countries

Netherlands

Outcome results